Problemy tuberkuleza i bolezneĭ legkikh
-
Probl Tuberk Bolezn Legk · Jan 2005
Comparative Study[Comparative efficiency of treatment with moxyfloxacin and lomefloxacin for generalized murine tuberculosis caused by drug-resistant Mycobacterium strains].
The antituberculous efficacy of the new fluoroquinolone agent moxyfloxacin was studied on a model of generalized murine tuberculosis caused by a multidrug-resistant Mycobacterium strain. There was evidence for the high therapeutic effect of moxyfloxacin and its advantages over the antituberculous agent lomefloxacin.
-
Probl Tuberk Bolezn Legk · Jan 2005
Case Reports[The specific features of the detection, clinical manifestations, and treatment of tuberculosis in the HIV-infected].
The present study has explored the specific features of the detection, clinical manifestations, and treatment of tuberculosis (TB) in 425 patients with TB and HIV infection. According to the time of joining the infections, the patients with TB and HIV infection are divided into 2 basic groups: 1) HIV infection is primary, TB develops at any stage of HIV infection and 2) TB is primary, HIV injections joins different forms of TB at its any stage. The social makeup of patients with TB/HIV infection is unfavorable: the unemployed, 50%; homeless persons, 26.5%; employees, 5%; workers, 9%; pensioners, 1.5%; the disabled, 5%; pupils, 3%. ⋯ Mortality rates in patients with TB and HIV infection are gradually on the rise and equal to 11.2% of the treated patients in 2001, 5% in 2002, 15.2% in 2003, and 19.6% in 2004. In patients with HIV/TB, the rates are higher than those in patients with TB/HIV and are 19.2 and 14.5%, respectively. Acutely progressive pulmonary TB and miliary TB of the lung and extrapulmonary organs and systems are a cause of death in most (76%) patients with TB/HIV.
-
Probl Tuberk Bolezn Legk · Jan 2005
Editorial Comparative Study Historical Article[Problems of tuberculosis in megapolis].